Effect of gender on phenotypic expression of the S447X mutation in LPL -: The Copenhagen City Heart Study

被引:42
|
作者
Wittrup, HH
Nordestgaard, BG
Steffensen, R
Jensen, G
Tybjærg-Hansen, A
机构
[1] Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem KB3011, DK-2100 Copenhagen O, Denmark
[2] Herlev Univ Hosp, Dept Clin Biochem, Copenhagen, Denmark
[3] Univ Copenhagen Hosp, Rigshosp, Div Cardiol, Dept Med B, Copenhagen O, Denmark
[4] Univ Copenhagen, Bispebjerg Hosp, Copenhagen City Heart Study, Copenhagen O, Denmark
基金
英国医学研究理事会;
关键词
atherosclerosis; coronary disease; genes; lipids; lipoproteins;
D O I
10.1016/S0021-9150(02)00183-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The G188E, D9N, and N291S mutations in LPL increase TG, reduce HDL cholesterol, and increase risk of ischemic heart disease. The common S447X mutation may have opposite effects. We genotyped 8451 women and men from the Danish general population, and 854 women and men with ischemic heart disease. Participants carrying G188E, D9N, or N291S were excluded. Compared with non-carriers, female heterozygotes and homozygotes presented with a 0.11 and 0.18 mmol/l decrease in plasma TG (P = 0.001 and P = 0.37) and a 0.07 and 0.03 mmol/l increase in HDL cholesterol (P = 0.001 and P = 0.99). Male heterozygotes and homozygotes presented with a 0.20 and 0.41 mmol decrease in plasma TG (P < 0.001 and P = 0.06), which was twice that in women, and a 0.05 and 0. 17 mmol/l increase in plasma HDL cholesterol (P = 0.02 and P = 0.04), respectively. In meta-analyses by gender, the S447X mutation was associated with a significant 17% reduction in risk of ischemic heart disease in men (OR = 0.83; P = 0.01), whereas risk was unaffected in women (OR = 0.97; P = 0.98). The S447X mutation is associated with anti-atherogenic effects on TG and HDL cholesterol in both genders, and with a moderate protective effect on risk of ischemic heart disease in men. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 46 条
  • [31] Long-Term Transgene Expression and Biological Effect Following IM Administration of AAV1-LPLS447X to LPL Deficient Patients
    Twisk, Jaap
    Frisch, Frederique
    Ferreira, Valerie
    van den Bulk, Nick
    Petry, Harald
    Carpentier, Andre C.
    Methot, Julie
    Brisson, Diane
    Gaudet, Daniel
    MOLECULAR THERAPY, 2012, 20 : S23 - S23
  • [32] A new ligand defective mutation in APOB associated with hypobetalipoproteinemia and reduced production and catabolism of LDL:: The Copenhagen City Heart study
    Benn, M
    Nordestgaard, BG
    Jensen, JS
    Tybjærg-Hansen, A
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (05) : A48 - A48
  • [33] The Effect of Occupational Lifting on Hypertension Risk: Protocol for a Project Using Data From the Copenhagen City Heart Study
    Korshoj, Mette
    Hannerz, Harald
    Marott, Jacob Louis
    Schnohr, Peter
    Prescott, Eva Irene Bossano
    Clays, Els
    Holtermann, Andreas
    JMIR RESEARCH PROTOCOLS, 2018, 7 (04):
  • [34] A mutation in the beta-fibrinogen promoter raises plasma fibrinogen, an independent risk factor for ischemic heart disease in men and women in the Copenhagen City Heart Study
    TybjaergHansen, A
    Reeler, S
    AgerholmLarsen, B
    Humphries, SE
    Schnohr, P
    Nordestgaard, BG
    CIRCULATION, 1996, 94 (08) : 4337 - 4337
  • [35] Absence of association between the S447X variant of the gene of lipoprotein lipase and plasma lipids. Preliminary study. Misprint. (vol 55, pg 136, 2014)
    Zambrano Morales, M.
    Fernandez Salgado, E.
    Balzan Urdaneta, L.
    Labastidas, N.
    Aranguren-Mendez, J.
    Connell, L.
    Molero Paredes, T.
    Rojas, A.
    Panunzio, A.
    INVESTIGACION CLINICA, 2014, 55 (03): : 291 - 291
  • [36] Digital X-ray radiogrammetry: Comparison of measurement in the dominant and the nondominant hand. Results from the Copenhagen city heart study
    Bach-Mortensen, P.
    Hyldstrup, L.
    Appleyard, M.
    Hindsoe, K.
    Gebuhr, P.
    Sonne-Holm, S.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S115 - S116
  • [37] Risk of ischemic heart and ischemic cerebrovascular disease is not increased in S, Z, and 11478A α1-antitrypsin -: Carriers of the Copenhagen City Heart Study
    Dahl, M
    Tybjærg-Hansen, A
    Nordestgaard, BG
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (11)
  • [38] A common mutation (G(-455)->A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease - A study of 9,127 individuals based on the Copenhagen city heart study
    TybjaergHansen, A
    AgerholmLarsen, B
    Humphries, SE
    Abildgaard, S
    Schnohr, P
    Nordestgaard, BG
    JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (12): : 3034 - 3039
  • [39] Risk of ischemic heart and ischemic cerebrovascular disease is not increased in S, Z, and 11478A α1-antitrypsin -: Carriers of the Copenhagen City Heart Study -: Response
    Talmud, PJ
    Wright, R
    Steiner, G
    Syvänne, M
    Humphries, SE
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (11)
  • [40] Two-fold risk of myocardial infarction in male carriers of the coagulation factor v Arg506Gln mutation: The Copenhagen city heart study
    Juul, K
    Tybjaerg-Hansen, A
    Steffensen, R
    Jensen, GB
    Nordestgaard, BG
    CIRCULATION, 1999, 100 (18) : 683 - 683